Salbutamol sulphate

The Main goal of the present study was to develop and evaluate the orally disintegrating mini-tablets (ODMTs) containing Salbutamol sulphate for the treatment of respiratory disorders like Asthma and Chronic obstructive pulmonary diseases. The problems associated with conventional oral dosage forms are associated with slow down onset of action and lag time, while parenterals and aerosol despite of quick-outset of action strongly affect the patient compliance. Quick release tablets are highly accepted rapid increasing drug delivery systems and thus, an attempt was made to improve the onset of action of drug. To reach this goal, selective superdisintegrants like Crospovidone and Sodium starch glycolate were used in different ratios. Micromeritic properties of the powder were within the limit confirmed by free flowing. ODMTs were compressed in order to have sufficient mechanical strength and integrity to withstand handling, shipping and transportation. The tablets were prepared by direct compression method and physicochemical properties were evaluated. FTIR and DSC studies were confirms no chemical interaction between the excipients and drug. Out of six formulations prepared tablet F3 resulted a least dissolution and disintegration time. Hence, concluded that ODMTs give the better effect to the asthma patients and may serve as a successful strategy for enhancing the bioavailability of drug.

  The present investigation deals with the preparation and evaluation of sustained release system of Salbutamol sulphate for the treatment of Asthama. The liposomes of Salbutamol sulphate were prepared using physical dispersion method by using soyalecithin and cholesterol. The ratio of soyalecithin and cholesterol was found to be important factors for achieving sustained release pattern. Factors studied influenced the lag time and in-vitro drug release of formulations. Dissolution studies of liposomes in phosphate buffer with pH 7.4 shows the drug release in colon could be modulated by optimizing the concentration of soyalecithin and cholesterol (6:1). The results of in-vitro dissolution studies indicated that formulation F1 is the most successful formulation of the study and exhibited drug release 96.24% in 12 h and the total release pattern was very close to the theoretical release profile of sustained release system. The study showed that the optimised batch F1 fulfills the requirement of good liposomal formulation. Stability study of the optimized formulation indicates no significant difference in release profile after a period of two month. Key words: Sustained release system, Soya lecithin: Cholesterol, Salbutamol sulphate, Liposomes